Virtual reality (VR) can identify early Alzheimer’s disease more accurately than ‘gold standard’ cognitive tests currently in use, suggests new research from the University of Cambridge.
The study highlights the potential of new technologies to help diagnose and monitor conditions such as Alzheimer’s disease, which affects more than 525,000 people in the UK.
In 2014, Professor John O’Keefe of UCL was jointly awarded the Nobel Prize in Physiology or Medicine for ‘discoveries of cells that constitute a positioning system in the brain’. Essentially, this means that the brain contains a mental ‘satnav’ of where we are, where we have been, and how to find our way around.
A key component of this internal satnav is a region of the brain known as the entorhinal cortex. This is one of the first regions to be damaged in Alzheimer’s disease, which may explain why ‘getting lost’ is one of the first symptoms of the disease. However, the pen-and-paper cognitive tests used in clinic to diagnose the condition are unable to test for navigation difficulties.
In collaboration with Professor Neil Burgess at UCL, a team of scientists at the Department of Clinical Neurosciences at the University of Cambridge led by Dr Dennis Chan, previously Professor O’Keefe’s PhD student, developed and trialled a VR navigation test in patients at risk of developing dementia. The results of their study are published today in the journal Brain.
In the test, a patient dons a VR headset and undertakes a test of navigation while walking within a simulated environment. Successful completion of the task requires intact functioning of the entorhinal cortex, so Dr Chan’s team hypothesised that patients with early Alzheimer’s disease would be disproportionately affected on the test.
The team recruited 45 patients with mild cognitive impairment (MCI) from the Cambridge University Hospitals NHS Trust Mild Cognitive Impairment and Memory Clinics. Patients with MCI typically exhibit memory impairment, but while MCI can indicate early Alzheimer’s, it can also be caused by other conditions such as anxiety and even normal aging. As such, establishing the cause of MCI is crucial for determining whether affected individuals are at risk of developing dementia in the future.
The researchers took samples of cerebrospinal fluid (CSF) to look for biomarkers of underlying Alzheimer’s disease in their MCI patients, with 12 testing positive. The researchers also recruited 41 age-matched healthy controls for comparison.
All of the patients with MCI performed worse on the navigation task than the healthy controls. However, the study yielded two crucial additional observations. First, MCI patients with positive CSF markers – indicating the presence of Alzheimer’s disease, thus placing them at risk of developing dementia – performed worse than those with negative CSF markers at low risk of future dementia.
Secondly, the VR navigation task was better at differentiating between these low and high risk MCI patients than a battery of currently-used tests considered to be gold standard for the diagnosis of early Alzheimer’s.
“These results suggest a VR test of navigation may be better at identifying early Alzheimer’s disease than tests we use at present in clinic and in research studies,” says Dr Chan.
VR could also help clinical trials of future drugs aimed at slowing down, or even halting, progression of Alzheimer’s disease. Currently, the first stage of drug trials involves testing in animals, typically mouse models of the disease. To determine whether treatments are effective, scientists study their effect on navigation using tests such as a water maze, where mice have to learn the location of hidden platforms beneath the surface of opaque pools of water. If new drugs are found to improve memory on this task, they proceed to trials in human subjects, but using word and picture memory tests. This lack of comparability of memory tests between animal models and human participants represents a major problem for current clinical trials.
“The brain cells underpinning navigation are similar in rodents and humans, so testing navigation may allow us to overcome this roadblock in Alzheimer’s drug trials and help translate basic science discoveries into clinical use,” says Dr Chan. “We’ve wanted to do this for years, but it’s only now that VR technology has evolved to the point that we can readily undertake this research in patients.”
In fact, Dr Chan believes technology could play a crucial role in diagnosing and monitoring Alzheimer’s disease. He is working with Professor Cecilia Mascolo at Cambridge’s Centre for Mobile, Wearable Systems and Augmented Intelligence to develop apps for detecting the disease and monitoring its progression. These apps would run on smartphones and smartwatches. As well as looking for changes in how we navigate, the apps will track changes in other everyday activities such as sleep and communication.
“We know that Alzheimer’s affects the brain long before symptoms become apparent,” says Dr Chan. “We’re getting to the point where everyday tech can be used to spot the warning signs of the disease well before we become aware of them.
“We live in a world where mobile devices are almost ubiquitous, and so app-based approaches have the potential to diagnose Alzheimer’s disease at minimal extra cost and at a scale way beyond that of brain scanning and other current diagnostic approaches.”
The Latest on: App-based diagnostics
via Google News
The Latest on: App-based diagnostics
- Real-time tracking of self-reported symptoms to predict potential COVID-19on May 11, 2020 at 2:16 am
Analysis of data from a smartphone-based app designed for large-scale tracking of potential COVID-19 symptoms, used by over 2.5 million participants in the United Kingdom and United States, shows that ...
- PRA Health Sciences Inc (PRAH) Q1 2020 Earnings Call Transcripton May 1, 2020 at 4:01 pm
Q1 2020 Earnings Call May 1, 2020, 9:00 a.m. ET Ladies and gentlemen, thank you for standing by, and welcome to the PRA Health Sciences First Quarter 2020 Earnings Release Conference Call. [Operator ...
- Coronavirus and the 'new normal': What's coming in the months aheadon May 1, 2020 at 9:15 am
The COVID-19 pandemic has already affected the lives of every American. And while politicians and experts disagree on how best to confront the disease and mitigate its economic ramifications, there is ...
- AIIMS to offer free tele-consultationon April 25, 2020 at 4:35 pm
Then, they will have to enter a One-Time Password (OTP) to authenticate, and enter patient details for the first time for app-based registration ... Mangalagiri Central Diagnostic Lab has made ...
- Diagnosis of TIA (DOT) Score – Design and Validation of a New Clinical Diagnostic Tool for Transient Ischaemic Attackon April 23, 2020 at 5:00 pm
The only available diagnostic score (Dawson et al) is limited in scope and not widely used. The Diagnosis of TIA (DOT) Score is a new and internally validated web and mobile app based diagnostic ...
- 'I don't see any other way out': Diagnostic testing and smartphone contact tracing to beat pandemicon April 20, 2020 at 5:03 am
He believes new diagnostic approaches ... your transmission chain has the freedom to travel and work." He said an app-based public health intervention of this kind would give Europe a chance ...
- Scientists Developing App Based On Sound Of COVID-19 Coughon April 15, 2020 at 8:47 am
Researchers with the Embedded Systems Laboratory at the Swiss Federal Institute of Technology Lausanne are developing a diagnostic test on a smartphone app that works by "listening" to the sound ...
- Scientists Developing App Based On Sound Of COVID-19 Coughon April 15, 2020 at 4:44 am
Scientists say they can distinguish the sound of a COVID-19 cough. Researchers are developing a diagnostic test on a smartphone app that works by “listening” to the sound of the user’s cough.
- How Ava is attempting to solve the Covid-19 testing crisison April 3, 2020 at 12:08 pm
As the world is engaged in a battle of life and death with the novel coronavirus, wearables could have a vital role to play. Hot on the heels of the Oura ...
via Bing News